Qritive

Qritive’s AI modules for digital pathology have been clinically validated for use in colon, prostate, breast, and gastric cancers. Their solutions are integrated with Roche navify® Digital Pathology platform to improve diagnostic accuracy and speed. Results presented at major conferences/journals include deep learning on prostate biopsies (USCAP), Ki67 on sarcomas, colorectal malignancies. The company reports up to a tenfold improvement in reporting time with significant reduction of misdiagnosis risk. Used by healthcare institutions across Singapore, India, Morocco, UAE & USA. No clinical trial pipeline as it provides diagnostic software rather than therapeutics.